---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-262543"
form_type: "8-K"
ticker: "FBRX"
cik: "0001419041"
company_name: "Forte Biosciences, Inc."
filed_at: "2024-11-20T23:59:59+00:00"
generated_at: "2026-05-29T21:43:30.173451+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Forte Biosciences raises $53M in oversubscribed private placement for FB102 clinical development

## Summary
- Gross proceeds ~$53M from shares and pre-funded warrants to institutional investors including OrbiMed, Janus Henderson, Tybourne.
- Private placement expected to close November 21, 2024; net proceeds for working capital and general corporate purposes.
- FB102 healthy volunteer study completed; celiac disease trial topline readout projected Q2 2025.
- Additional indications expected over next 12 months; R&D Day on December 3, 2024.
- CEO Paul Wagner says financing is transformative and well capitalized for continued advancement.

## SEC filing metadata
- accession: 0001193125-24-262543
- form_type: 8-K
- ticker: FBRX
- cik: 0001419041
- company_name: Forte Biosciences, Inc.
- filed_at: 2024-11-20T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 1.01, 3.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1419041/000119312524262543/0001193125-24-262543-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1419041/000119312524262543/d815860d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-262543
- JSON: https://secwatch.observer/filing/0001193125-24-262543.json
- Plain text: https://secwatch.observer/filing/0001193125-24-262543.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.